The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II clinical study of concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: Results for primary analyses and survival. BTCRC-GU15-023.
Monika Joshi
Research Funding - AstraZeneca (Inst); Eisai (Inst); Pfizer (Inst)
Matthew Kaag
No Relationships to Disclose
Leonard Tuanquin
No Relationships to Disclose
Jason Liao
No Relationships to Disclose
Deepak Kilari
Honoraria - Exelixis
Consulting or Advisory Role - Exelixis; Merck Sharp & Dohme; Myovant Sciences; Sanofi
Speakers' Bureau - Astellas Pharma; Exelixis; Genzyme; Genzyme (Inst); Janssen
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Genentech
Travel, Accommodations, Expenses - Bayer; Clovis Oncology; Exelixis; Janssen; Sanofi
Hamid Emamekhoo
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Cardinal Health; Exelixis; Exelixis
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - DAVA Pharmaceuticals
Alexander Sankin
No Relationships to Disclose
Suzanne B Merrill
No Relationships to Disclose
Hong Zheng
Consulting or Advisory Role - BeiGene
Research Funding - Pfizer
Sheldon L. Holder
Employment - Hope Healthcare
Research Funding - Lilly
Joshua Warrick
No Relationships to Disclose
Ralph J. Hauke
Stock and Other Ownership Interests - Aethlon
Honoraria - Best Doctors, Inc
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst); US Oncology (Inst)
Benjamin Adam Gartrell
No Relationships to Disclose
Mark N. Stein
Consulting or Advisory Role - Exelixis; Exelixis; Merck Sharp & Dohme; Xencor
Research Funding - Advaxis (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Seattle Genetics (Inst); Suzhou Kintor Pharmaceuticals (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst)
Joseph J. Drabick
Consulting or Advisory Role - Sanofi/Aventis
David Degraff
No Relationships to Disclose
Yousef Zakharia
Consulting or Advisory Role - Amgen; Bayer; Cardinal Health; Castle Biosciences; Clovis Oncology; Eisai; Exelixis; Janssen; Novartis; Pfizer; Roche/Genentech; TTC Oncology
Travel, Accommodations, Expenses - Newlink Genetics